| Literature DB >> 26335572 |
Yongnan Li1, Min Li2, Shuodong Wu3, Yu Tian4.
Abstract
BACKGROUND: A disruption of cholesterol homeostasis characterized by the physical-chemical imbalance of cholesterol solubility in bile often results in formation of cholesterol gallstones. Our earlier studies revealed that curcumin (1000 mg/kg) could prevent formation of gallstones. It has been proved that curcumin is poorly absorbed while piperine is a bioavailability-enhancer. Nevertheless, whether curcumin combined with piperine could enhance the effect of curcumin in preventing gallstones is still awaited.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26335572 PMCID: PMC4557223 DOI: 10.1186/s12944-015-0106-2
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Lipid levels of bile and serum
| Bile(mmol/L)* | Serum(mmol/L) n = 10 | ||||
|---|---|---|---|---|---|
| Cholesterol | Phospholipid | Bile acid | Cholesterol | Triglyceride | |
| CD | 5.73 | 29.64 | 154.47 | 2.45 ± 0.31 | 0.27 ± 0.03 |
| LD | 18.64 | 28.93 | 138.64 | 6.86 ± 0.16** | 1.59 ± 0.10** |
| LP20 | 15.92 | 29.79 | 143.24 | 5.80 ± 0.79*** | 1.56 ± 0.12 |
| LC500 | 16.29 | 30.13 | 141.59 | 6.56 ± 0.42 | 1.58 ± 0.09 |
| LC500P20 | 6.39 | 31.95 | 163.29 | 2.89 ± 0.14*** | 0.84 ± 0.10*** |
| LC1000 | 6.59 | 32.24 | 161.35 | 2.96 ± 0.08*** | 0.84 ± 0.10*** |
*It was calculated by molarity, and the bile was collected for each experimental group
**P < 0.001 compared with CD
***P < 0.001 compared with LD
Biliary lipid compositions of gallbladder bile
| Cholesterol | Phospholipid | Bile salt | Cholesterol | Total lipid concentration(g/dL) | CSI | ||
|---|---|---|---|---|---|---|---|
| (Mole%a) | (Mole%a) | (Mole%a) | Phospholipid | Bile salt | |||
| CD | 3.02 | 15.61 | 81.37 | 0.20 | 0.04 | 10.1 | 0.546 |
| LD | 10.01 | 15.54 | 74.45 | 0.64 | 0.13 | 9.77 | 1.712 |
| LP20 | 8.43 | 15.77 | 75.81 | 0.53 | 0.11 | 9.96 | 1.465 |
| LC500 | 8.66 | 16.03 | 75.31 | 0.54 | 0.11 | 9.92 | 1.476 |
| LC500P20 | 3.17 | 15.85 | 80.98 | 0.2 | 0.04 | 10.74 | 0.554 |
| LC1000 | 3.29 | 16.11 | 80.6 | 0.20 | 0.04 | 10.68 | 0.575 |
aMole fraction
Fig. 1The relative lipid compositions of pooled gallbladder bile. ● represents relative lipid compositions of pooled gallbladder bile at 4 weeks in LD, Δ for LP20; ◆ for LC500; ◇ for LC500P20; ○ for LC1000; ▇ for CD
Prevention of cholesterol gallstones by curcumin and piperine
| Incidence of cholesterol gallstones(%) | Reduction in incidence of cholesterol gallstones(%) | |
|---|---|---|
| CD | 0 | - |
| LD | 100 % | - |
| LP20 | 70 % | 30 % |
| LC500 | 80 % | 20 % |
| LC500P20 | 30 % | 70 % |
| LC1000 | 40 % | 60 % |
There are 10 mice per group
Volume of gallbladder and weight of liver
| Gallbladder ( | Liver ( | |||
|---|---|---|---|---|
| Length(mm) | Width(mm) | Volume(μL) | Weight(g) | |
| CD | 6.35 ± 0.91 | 2.75 ± 0.32 | 25.24 ± 5.97 | 0.90 ± 0.07 |
| LD | 8.19 ± 1.71 | 3.87 ± 0.48 | 65.54 ± 22.69* | 1.93 ± 0.18* |
| LP20 | 7.36 ± 1.51 | 3.61 ± 0.70 | 53.90 ± 28.08 | 1.32 ± 0.18*** |
| LC500 | 7.91 ± 0.87 | 3.66 ± 0.50 | 61.41 ± 18.44 | 1.90 ± 0.16 |
| LC500P20 | 6.66 ± 1.36 | 3.09 ± 0.57 | 35.98 ± 15.27** | 1.15 ± 0.19*** |
| LC1000 | 7.18 ± 1.04 | 3.49 ± 0.72 | 49.05 ± 25.01 | 1.23 ± 0.13*** |
Values are means ± SD, with 10 samples each group
*P < 0.001 compared with CD, **P < 0.05 compared with LD, ***P < 0.001 compared with LD
Fig. 2HE staining and sirius red saturated picric acid staining in liver and gallbladder
Fig. 3Changes of liver and gallbladder in different groups. LD: Liver underwent hepatic steatosis and gallbladder stones formed. LP20: Liver appeared normal, while gallbladder stones were observed. LC500P20: Liver appeared normal and no stones were seen in gallbladder. LC1000: Liver underwent fatty degeneration and no stones were observed
Fig. 4Curcumin combined with piperine reduces NPC1L1 expression. a NPC1L1 mRNA levels. b NPC1L1 protein expression. c Grey analysis for western blot
Fig. 5Curcumin combined with piperine reduces SREBP2 expression. a SREBP2 mRNA expression. b SREBP2 protein expression. c Grey analysis for western blot